Children randomised to heterologous or homologous 2-dose hepatitis B schedules (2 and 12 months) had seroprotection similar to a 3-dose control group one month after the series (91.7%, 90.9%, 94.2%), with similar anamnestic responses 3 years later.
RCT
Kegbevi et al. Immunogenicity of Two Versus Three Doses of Hepatitis B Vaccine When Administered to Children Aged 2-18 Months: A Randomized Clinical Trial